Q3 EPS Forecast for Aquestive Therapeutics Lifted by Analyst

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – HC Wainwright lifted their Q3 2026 earnings per share estimates for Aquestive Therapeutics in a note issued to investors on Monday, August 24th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.09) for the quarter, up from their prior estimate of ($0.13). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.50) per share. HC Wainwright also issued estimates for Aquestive Therapeutics’ Q4 2026 earnings at ($0.09) EPS, FY2026 earnings at ($0.43) EPS, Q1 2027 earnings at ($0.09) EPS, Q2 2027 earnings at ($0.10) EPS, Q4 2027 earnings at ($0.10) EPS and FY2027 earnings at ($0.39) EPS.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.08). The firm had revenue of $13.82 million during the quarter, compared to the consensus estimate of $11.42 million.

Several other equities research analysts have also weighed in on AQST. Wall Street Zen lowered shares of Aquestive Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Friday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Aquestive Therapeutics currently has a consensus rating of “Buy” and an average price target of $8.80.

Aquestive Therapeutics Stock Performance

Shares of NASDAQ AQST opened at $5.08 on Wednesday. The stock has a market cap of $637.59 million, a P/E ratio of -7.82 and a beta of 1.49. The firm has a 50 day moving average price of $4.21 and a 200 day moving average price of $4.14. Aquestive Therapeutics has a 52-week low of $2.93 and a 52-week high of $7.55.

Hedge Funds Weigh In On Aquestive Therapeutics

Several hedge funds have recently made changes to their positions in the business. NewEdge Advisors LLC bought a new stake in shares of Aquestive Therapeutics in the third quarter worth $28,000. BNP Paribas Financial Markets lifted its position in Aquestive Therapeutics by 78.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock worth $31,000 after buying an additional 4,134 shares in the last quarter. Modern Wealth Management LLC bought a new stake in Aquestive Therapeutics during the 2nd quarter worth about $33,000. Elevation Point Wealth Partners LLC acquired a new position in shares of Aquestive Therapeutics during the 1st quarter worth about $42,000. Finally, ADAR1 Capital Management LLC increased its position in shares of Aquestive Therapeutics by 103.9% in the first quarter. ADAR1 Capital Management LLC now owns 10,000 shares of the company’s stock valued at $42,000 after acquiring an additional 264,000 shares during the last quarter. 32.45% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Julie Krop sold 25,000 shares of the stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $5.02, for a total transaction of $125,500.00. Following the completion of the transaction, the director directly owned 25,000 shares in the company, valued at approximately $125,500. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.81% of the company’s stock.

Aquestive Therapeutics News Summary

Here are the key news stories impacting Aquestive Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to a loss of $0.43 from a loss of $0.51 and lifted its FY2027 estimate to a loss of $0.39 from a loss of $0.52. The revisions indicate expectations for narrower losses and improving profitability. HC Wainwright Reiterates Buy Rating for Aquestive Therapeutics
• Positive Sentiment: The analyst also improved quarterly forecasts: Q3 2026 EPS was raised to a loss of $0.09 from $0.13, Q4 2026 to a loss of $0.09 from $0.15, Q1 2027 to a loss of $0.09 from $0.15, and Q2 2027 to a loss of $0.10 from $0.15. The Q4 2027 estimate increased to a loss of $0.10 from $0.11.
• Positive Sentiment: HC Wainwright’s $10 target represents approximately 96.9% potential upside from the referenced $5.08 price, reinforcing the firm’s bullish view. Benzinga analyst-rating report
• Positive Sentiment: A recent report noted that AQST shares increased 5.02%, reflecting continued investor interest in the company and its outlook. Why Aquestive Therapeutics Stock Is Up 5.02%

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.